Abstract 287P
Background
HER2+ tumors make up approximately 20% of MBCs. The survival outcomes for HER2+ MBC patients improved significantly in the last decade due to the development of HER2-targeted therapies. The objective of this SLR was to assess recent evidence on the burden of HER2+ MBC.
Methods
A SLR was conducted in MEDLINE and EMBASE databases (2010-2020) and congress abstract repositories (2018-2020). The search adhered to Preferred Reporting Item for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A total of 8,115 records were identified, of which 6,549 were retrieved upon deduplication. Two reviewers independently screened titles and abstracts for eligibility. Full-text review of 571 articles was then carried out.
Results
260 studies met the inclusion criteria. Seven sources of which compared HER2+ mBC patients to the general and BC populations reporting impaired health utility scores and moderate or worse health status. This was assessed using a variety of tools, such as EQ-5D-5L, FACT-B and EORTC QLQ-C30. In addition to lower Quality of Life (QoL), the disease is associated with impairment of work- and daily activity, negative body image perception, and mental disorders. The symptoms, comorbidities and treatment adverse events most frequently reported by HER2+ mBC patients include tiredness, decreased sexual interest, lack of energy, sore muscles, worry, difficulty sleeping and joint pain. Due to the longer treatment duration and high treatment costs of anti-HER2 treatments, HER2+ MBC leads to greater costs than other types of mBC. In Europe, overall-per-patient costs of HER2+ mBC per patient were €235,238-€269,749, of which €37,431-53,950 were annual treatment costs. Costs are primarily driven by treatment and hospitalization costs, and accumulatively increase by line of treatment.
Conclusions
With improvements in disease management being made in recent years, the SLR demonstrated that a substantial burden of HER2+ MBC on patients’ QoL and on the healthcare systems still exists, highlighting the need for more cost-effective treatment options.
Clinical trial identification
Editorial acknowledgement
Despina Biri, Medical Writer, Asc Academics.
Legal entity responsible for the study
Gert Vondeling, Daiichi Sankyo Europe.
Funding
Daiichi Sankyo Europe GmbH.
Disclosure
G. Vondeling, A. Seddik: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo Europe GmbH. T. Harding: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. K. Bakker, R. Velikanova: Financial Interests, Full or part-time Employment: Asc Academics.